J. List
Endocrinology, Diabetes and Metabolism · 2008–2013
A researcher in the Science corpus: 5 papers; trusts 2 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 14 citations into it; #286 of 623 by trust here, #290 by citations
- Molecular Biology — 8 citations into it
- Surgery — 7 citations into it
Whom J. List trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts J. List overall
Papers from J. List's perspective
Ordered by how strongly the researchers J. List trusts endorse each paper. Same corpus, a different order for every researcher.
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study (British medical journal)
- Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. (Journal of the American Medical Association (JAMA))
- Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins (British Journal of Nutrition)
- Oral antihyperglycemic therapy for type 2 diabetes: scientific review. (Journal of the American Medical Association (JAMA))
- Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. (Journal of Clinical Endocrinology and Metabolism)
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes (Diabetes Care)
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (Diabetes Care)
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. (Diabetes Care)
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a… (Diabetes, obesity and metabolism)
- Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. (Journal of Clinical Endocrinology and Metabolism)
Their papers
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control (2013) — 657 citations
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes (2013) — 767 citations
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. (2010) — 875 citations
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise (2010) — 750 citations
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes (2008) — 690 citations